Global Blood Therapeutics Inc (NASDAQ:GBT) – Stock analysts at Oppenheimer issued their FY2022 earnings estimates for Global Blood Therapeutics in a research report issued to clients and investors on Thursday. Oppenheimer analyst M. Breidenbach anticipates that the company will post earnings per share of $4.30 for the year. Oppenheimer currently has a “Buy” rating and a $79.00 target price on the stock.
Global Blood Therapeutics (NASDAQ:GBT) last issued its quarterly earnings results on Thursday, November 2nd. The company reported ($0.66) EPS for the quarter, missing analysts’ consensus estimates of ($0.62) by ($0.04). During the same quarter in the previous year, the firm earned ($0.58) earnings per share.
Shares of Global Blood Therapeutics (NASDAQ:GBT) traded up $0.15 on Friday, reaching $56.60. The company had a trading volume of 968,595 shares, compared to its average volume of 1,600,000. The stock has a market capitalization of $2,600.00 and a P/E ratio of -22.20. Global Blood Therapeutics has a 1 year low of $14.70 and a 1 year high of $57.75.
Institutional investors have recently made changes to their positions in the company. BNP Paribas Arbitrage SA raised its position in shares of Global Blood Therapeutics by 694.9% during the 2nd quarter. BNP Paribas Arbitrage SA now owns 4,547 shares of the company’s stock worth $124,000 after purchasing an additional 3,975 shares during the period. Jane Street Group LLC acquired a new stake in shares of Global Blood Therapeutics during the 3rd quarter worth approximately $200,000. Trexquant Investment LP acquired a new stake in shares of Global Blood Therapeutics during the 3rd quarter worth approximately $202,000. Dynamic Technology Lab Private Ltd acquired a new stake in shares of Global Blood Therapeutics during the 3rd quarter worth approximately $205,000. Finally, Virtu KCG Holdings LLC acquired a new stake in shares of Global Blood Therapeutics during the 2nd quarter worth approximately $219,000. Institutional investors and hedge funds own 85.72% of the company’s stock.
In other news, Director Charles J. Homcy sold 70,000 shares of the stock in a transaction that occurred on Friday, October 27th. The stock was sold at an average price of $33.97, for a total transaction of $2,377,900.00. Following the sale, the director now directly owns 83,328 shares in the company, valued at approximately $2,830,652.16. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Jung Choi sold 3,000 shares of the stock in a transaction that occurred on Tuesday, October 17th. The stock was sold at an average price of $32.65, for a total value of $97,950.00. Following the sale, the insider now owns 138,455 shares in the company, valued at $4,520,555.75. The disclosure for this sale can be found here. Insiders have sold 103,500 shares of company stock worth $3,773,000 in the last 90 days. 5.30% of the stock is currently owned by insiders.
Global Blood Therapeutics Company Profile
Global Blood Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering, developing and commercializing therapeutics to treat blood-based disorders. The Company is developing its initial product candidate, GBT440, as an oral, once-daily therapy for sickle cell disease (SCD).
What are top analysts saying about Global Blood Therapeutics? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Global Blood Therapeutics and related companies.